Andries M. Bergman

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 116 publications

Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry.

Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 29, 2026

Germline CDK12 variants in aggressive prostate cancer.

Germline CDK12 variants in aggressive prostate cancer.

Journal: Cancer discovery

Published: January 14, 2026

DEprot: a comprehensive R-package for the analysis of label-free quantitation mass spectrometry data.

DEprot: a comprehensive R-package for the analysis of label-free quantitation mass spectrometry data.

Journal: NAR genomics and bioinformatics

Published: November 05, 2025

Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.

Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 26, 2025

A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.

A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.

Journal: Oncogene

Published: May 18, 2025

Development of Radiomics Models to Predict Progression-Free Survival and Early Polymetastatic Progression in Patients With Lung Oligometastases Treated on the Single-Arm Phase II Stereotactic Ablative Radiotherapy-5 Trial.

Development of Radiomics Models to Predict Progression-Free Survival and Early Polymetastatic Progression in Patients With Lung Oligometastases Treated on the Single-Arm Phase II Stereotactic Ablative Radiotherapy-5 Trial.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: May 10, 2025

Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.

Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.

Journal: European urology oncology

Published: April 30, 2025

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 05, 2025

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice.

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: March 05, 2025

TRIM33 loss reduces androgen receptor transcriptional output and H2BK120 ubiquitination.

TRIM33 loss reduces androgen receptor transcriptional output and H2BK120 ubiquitination.

Journal: Communications biology

Published: January 14, 2025

Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer.

Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer.

Journal: European urology oncology

Published: January 03, 2025

Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.

Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.

Journal: British journal of cancer

Published: September 27, 2024

Showing 1-12 of 116

Last Updated: 09/26/2026